VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Rugo Discusses MONARCH I in HR+ HER2- Breast Cancer

Hope S. Rugo, MD
Published: Friday, Apr 07, 2017



Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

The final overall analysis of the phase II study of abemaciclib, a CDK4/6 inhibitor, showed an overall survival of about 22 months.

This trial suggests that abemaciclib has significant single-agent activity. Additionally, this agent may improve progression-free survival when combined with hormone therapy such as fulvestrant (Faslodex), says Rugo.
 


Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

The final overall analysis of the phase II study of abemaciclib, a CDK4/6 inhibitor, showed an overall survival of about 22 months.

This trial suggests that abemaciclib has significant single-agent activity. Additionally, this agent may improve progression-free survival when combined with hormone therapy such as fulvestrant (Faslodex), says Rugo.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x